Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q3 2021 · 10-Q
Revenue$0.00$0.00−100.0% vs Q3 2020 Net Income-$3.74M-$3.74MN/M vs Q3 2020 EPS Diluted-$2.09-$2.09N/M vs Q3 2020 Operating Income-$3,746,660N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
ended Sep 30, 2021 · filed Nov 4, 2021 · 35 d after period end